147 related articles for article (PubMed ID: 35186714)
1. Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the
Nair R; Bhurani D; Rajappa S; Kapadia A; Reddy Boya R; Sundaram S; Menon H; Raman GS; Seshachalam A; Nimmagadda R
Front Oncol; 2021; 11():796962. PubMed ID: 35186714
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of diffuse large B-cell lymphoma in elderly patients-real-world experience from a middle-income country setting.
Sarker C; Radhakrishnan VS; Mandal P; Kumar J; Bhave S; Achari R; Dey D; Arun I; Latif Z; Arora N; Mishra D; Chandy M; Nair R
Ecancermedicalscience; 2021; 15():1242. PubMed ID: 34267798
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.
Bhurani D; Nair R; Rajappa S; Rao SA; Sridharan N; Boya RR; Raman GS; Menon H; Seshachalam A; Nimmagadda R
Front Oncol; 2021; 11():799948. PubMed ID: 35223455
[TBL] [Abstract][Full Text] [Related]
4. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
6. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
7. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India.
Nimmagadda RB; Digumarti R; Nair R; Bhurani D; Raina V; Aggarwal S; Patil S; Gogoi PK; Sundaram S; Goswami C; Apte S; Chakravarthy S; Pathak A
Indian J Med Paediatr Oncol; 2013 Oct; 34(4):299-304. PubMed ID: 24604961
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
9. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India.
Gogia A; Nair S; Arora S; Kumar L; Sharma A; Gupta R; Biswas A; Mallick S
Front Oncol; 2021; 11():770747. PubMed ID: 34926277
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma: A retrospective study from a regional care center in South India.
Babu SM; Garg S; Kanakasetty GB; Kuntegowdanahalli LC; Dasappa L; Rao SA
Indian J Cancer; 2018; 55(1):66-69. PubMed ID: 30147096
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma: An institutional analysis.
Gogia A; Das CK; Kumar L; Sharma A; Tiwari A; Sharma MC; Mallick S
South Asian J Cancer; 2018; 7(3):200-202. PubMed ID: 30112341
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
17. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
18. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
19. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.
Yi HG; Kim JS; Suh C; Kim WS; Kwak JY; Lee JS; Kim YS; Joo YD; Min YH; Lee HG; Yoon SS; Won JH; Park S; Kim HC; Kim CS
Blood Res; 2013 Jun; 48(2):115-20. PubMed ID: 23826580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
